Biogen Inc. Stock
€166.00
Your prediction
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 0.830% | 0.969% | 8.501% | 52.656% | 9.870% | -42.272% | -28.666% |
| BioMarin Pharmaceutical Inc. | 0.040% | -1.019% | -2.934% | -13.147% | -10.314% | -47.757% | -27.951% |
| Zoetis Inc. A | 1.510% | -14.593% | -38.111% | -54.174% | -40.797% | -62.435% | -55.192% |
| Elanco Animal Health Inc. | -5.080% | -9.115% | -9.071% | 59.751% | -3.782% | 135.380% | -35.119% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease
Best Healthcare Stocks to Buy in 2026
Biogen (NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a value-oriented play focusing on specialized neurology, while the other is
Why Biogen Stock Was a Winner on Wednesday
Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by